August 2012
-
Submit proposals for short courses, roundtables, symposia, mini-symposia, and sunrise sessions at http://abstracts.aapspharmaceutica.com/aaps2012/login.asp by November 7, 2011. For any additional information, contact Bethany Daniel. Read more . . .
-
A Phase 1 clinical trial of a novel dry powder intranasal vaccine for prevention of the H5N1 influenza strain demonstrated that the product was well tolerated, and no serious adverse events occurred, according to developer… Read more . . .
-
The board of directors of contract research organization PPD has approved a $3.9 billion all cash deal which will take the company private after its acquisition by the Carlyle Group and Hellman & Friedman. PPD… Read more . . .
-
According to the British Pharmacopoeia website: “The British Pharmacopoeia Commission has recently endorsed the formation of a new Working Party for Inhaled Products (IP). The remit of the Working Party will be to review the… Read more . . .
-
As Nycomed officially becomes a wholly owned subsidiary of Takeda Pharmaceutical Company, Takeda has named Frank Morich as the new Nycomed CEO. Morich will also continue in his current position as Executive VP (EVP) of… Read more . . .
-
The International Primary Care Respiratory Group (IPCRG) has launched a petition in support of its Fresh Air Uganda study in response to what it says is a growing threat in the region, with COPD expected… Read more . . .
-
Graceway Pharmaceuticals, which manufactures the MaxAir Autohaler pirbuterol acetate MDI, one of the last remaining CFC-propelled metered dose inhalers, has agreed to sell all of its assest to Galderma, a ” company focused exclusively on… Read more . . .
-
Massachusetts biotech company Pulmatrix presented data from two studies of its Pulmatrix presents data from preclinical studies of its lead product, PUR118, an inhaled cationic airway lining modulator (iCALM) for the treatment of respiratory diseases… Read more . . .
-
Novartis has filed a marketing authorization application (MAA) with the European Medicines Agency (EMA) for its NVA237 glycopyrronium bromide dry powder inhaler, which will be called the Seebri Breezhaler. The MAA once-daily long-acting antimuscarinic (LAMA)… Read more . . .
-
Almirall has presented a number of posters at the 2011 Annual Congress of the European Respiratory Society (ERS), including, for the first time, full data from the six-month Phase 3 ATTAIN study of its aclidinium… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland